Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brachytherapy | 3 | 2023 | 121 | 1.560 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2023 | 296 | 1.380 |
Why?
|
| Androgen Antagonists | 2 | 2017 | 154 | 0.990 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 1194 | 0.800 |
Why?
|
| Mastectomy | 2 | 2020 | 245 | 0.770 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 58 | 0.760 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.740 |
Why?
|
| Prostatic Neoplasms | 3 | 2017 | 1769 | 0.720 |
Why?
|
| Treatment Refusal | 1 | 2020 | 62 | 0.700 |
Why?
|
| Endometrial Neoplasms | 2 | 2019 | 205 | 0.690 |
Why?
|
| Ossification, Heterotopic | 1 | 2019 | 33 | 0.680 |
Why?
|
| Dilatation | 2 | 2019 | 48 | 0.660 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 109 | 0.660 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 128 | 0.640 |
Why?
|
| Urethral Neoplasms | 1 | 2018 | 10 | 0.630 |
Why?
|
| Hodgkin Disease | 2 | 2016 | 181 | 0.620 |
Why?
|
| Vagina | 2 | 2019 | 173 | 0.600 |
Why?
|
| Sarcoma | 1 | 2019 | 220 | 0.600 |
Why?
|
| Radiotherapy Dosage | 6 | 2023 | 470 | 0.590 |
Why?
|
| Radiotherapy | 1 | 2019 | 333 | 0.590 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 3011 | 0.580 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2015 | 176 | 0.580 |
Why?
|
| Rectal Neoplasms | 2 | 2015 | 127 | 0.570 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 171 | 0.550 |
Why?
|
| Sexuality | 1 | 2014 | 41 | 0.480 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 2018 | 0.470 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 1096 | 0.460 |
Why?
|
| Radiation Injuries | 1 | 2015 | 162 | 0.460 |
Why?
|
| Urinary Bladder | 1 | 2015 | 246 | 0.450 |
Why?
|
| Urinary Incontinence | 1 | 2015 | 213 | 0.440 |
Why?
|
| Middle Aged | 13 | 2021 | 25974 | 0.440 |
Why?
|
| Radiation Oncology | 3 | 2019 | 121 | 0.440 |
Why?
|
| Cranial Irradiation | 1 | 2011 | 40 | 0.380 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 601 | 0.370 |
Why?
|
| Quality of Life | 3 | 2021 | 1668 | 0.350 |
Why?
|
| Female | 17 | 2023 | 46202 | 0.340 |
Why?
|
| Humans | 23 | 2023 | 89357 | 0.340 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2284 | 0.330 |
Why?
|
| Sexism | 2 | 2019 | 53 | 0.330 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 860 | 0.290 |
Why?
|
| Constriction, Pathologic | 2 | 2019 | 217 | 0.280 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 782 | 0.250 |
Why?
|
| Chemoradiotherapy | 2 | 2019 | 309 | 0.240 |
Why?
|
| Aged | 6 | 2019 | 19165 | 0.220 |
Why?
|
| Uterus | 2 | 2021 | 222 | 0.220 |
Why?
|
| Hysterectomy | 2 | 2020 | 151 | 0.210 |
Why?
|
| Prospective Studies | 3 | 2015 | 4289 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 296 | 0.200 |
Why?
|
| Genital Neoplasms, Female | 1 | 2023 | 108 | 0.190 |
Why?
|
| Radiation Oncologists | 1 | 2021 | 14 | 0.190 |
Why?
|
| Pregnancy, Animal | 1 | 2001 | 58 | 0.190 |
Why?
|
| Integrative Medicine | 1 | 2021 | 10 | 0.190 |
Why?
|
| Risk Factors | 3 | 2020 | 5499 | 0.190 |
Why?
|
| Labor, Obstetric | 1 | 2001 | 46 | 0.190 |
Why?
|
| Patient Care Planning | 1 | 2021 | 83 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2019 | 8241 | 0.180 |
Why?
|
| Male | 9 | 2019 | 42411 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2624 | 0.180 |
Why?
|
| Complementary Therapies | 1 | 2021 | 56 | 0.180 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2001 | 152 | 0.180 |
Why?
|
| Dogs | 1 | 2001 | 704 | 0.180 |
Why?
|
| Perception | 1 | 2021 | 179 | 0.170 |
Why?
|
| Knee Prosthesis | 1 | 2019 | 32 | 0.170 |
Why?
|
| Ultrasonography, Mammary | 1 | 2020 | 83 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 49 | 0.170 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 306 | 0.170 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2019 | 49 | 0.160 |
Why?
|
| SEER Program | 2 | 2016 | 197 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 502 | 0.160 |
Why?
|
| Physicians, Women | 1 | 2019 | 56 | 0.160 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 114 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2021 | 9057 | 0.140 |
Why?
|
| Mammography | 1 | 2020 | 472 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2015 | 899 | 0.130 |
Why?
|
| Adult | 5 | 2021 | 26607 | 0.130 |
Why?
|
| Prognosis | 3 | 2019 | 3783 | 0.130 |
Why?
|
| Organs at Risk | 1 | 2015 | 40 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 360 | 0.120 |
Why?
|
| Anus Neoplasms | 1 | 2015 | 36 | 0.120 |
Why?
|
| Postoperative Period | 1 | 2015 | 302 | 0.120 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2014 | 30 | 0.120 |
Why?
|
| Pelvis | 1 | 2015 | 96 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2018 | 1534 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2015 | 337 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 78 | 0.120 |
Why?
|
| Time Factors | 2 | 2015 | 5338 | 0.120 |
Why?
|
| Health Surveys | 1 | 2014 | 240 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3666 | 0.100 |
Why?
|
| Massachusetts | 1 | 2011 | 33 | 0.100 |
Why?
|
| Hospitals, General | 1 | 2011 | 12 | 0.100 |
Why?
|
| Retreatment | 1 | 2011 | 108 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1072 | 0.090 |
Why?
|
| Steroids | 1 | 2011 | 174 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6811 | 0.090 |
Why?
|
| United States | 3 | 2019 | 6989 | 0.090 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 111 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2415 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2011 | 344 | 0.080 |
Why?
|
| Remission Induction | 1 | 2011 | 740 | 0.080 |
Why?
|
| Radiography | 1 | 2011 | 809 | 0.080 |
Why?
|
| Palliative Care | 1 | 2011 | 264 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1549 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2014 | 590 | 0.070 |
Why?
|
| Disease Progression | 1 | 2011 | 1489 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 851 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 1109 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 981 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 1120 | 0.050 |
Why?
|
| Progesterone | 1 | 2001 | 110 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 3041 | 0.050 |
Why?
|
| Fetus | 1 | 2001 | 232 | 0.040 |
Why?
|
| Gestational Age | 1 | 2001 | 329 | 0.040 |
Why?
|
| Self Care | 1 | 2021 | 165 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2019 | 8 | 0.040 |
Why?
|
| Women's Rights | 1 | 2019 | 7 | 0.040 |
Why?
|
| Pain Management | 1 | 2021 | 138 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 22 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 76 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2362 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 220 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 487 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2019 | 186 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 1528 | 0.040 |
Why?
|
| Mortality | 1 | 2016 | 149 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 216 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 93 | 0.030 |
Why?
|
| Sacrum | 1 | 2014 | 43 | 0.030 |
Why?
|
| Radiometry | 1 | 2014 | 56 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 223 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2014 | 43 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 98 | 0.030 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 84 | 0.030 |
Why?
|
| Femur | 1 | 2014 | 111 | 0.030 |
Why?
|
| Pregnancy | 1 | 2001 | 3018 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 238 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 969 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 445 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 561 | 0.030 |
Why?
|
| Radiosurgery | 1 | 2016 | 288 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1365 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 841 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2016 | 551 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1431 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2340 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2019 | 1045 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3160 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3731 | 0.020 |
Why?
|
| Child | 1 | 2016 | 7174 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2566 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 6312 | 0.010 |
Why?
|
| Animals | 1 | 2001 | 27371 | 0.010 |
Why?
|